| 1 |
Goyal R, Papamatheakis DG, Loftin M, et al. Long-term maternal hypoxia: the role of extracellular Ca2＋ entry during serotonin-mediated contractility in fetal ovine pulmonary arteries[J]. Reprod Sci, 2011, 18(10): 948-962.
|
| 2 |
Spiekerkoetter E, Kawut SM, de Jesus PV. New and Emerging Therapies for Pulmonary Arterial Hypertension[J]. Annu Rev Med, 2019, 70: 45-59.
|
| 3 |
Taichman DB, Ornelas J, Chung L, et al. Pharmacologic therapy for pulmonary arterial hypertension in adults: CHEST guideline and expert panel report[J]. Chest, 2014, 146(2): 449-475.
|
| 4 |
Ghosh S, Gupta M, Xu W, et al. Phosphorylation inactivation of endothelial nitric oxide synthesis in pulmonary arterial hypertension[J]. Am J Physiol Lung Cell Mol Physiol, 2016, 310(11): L1199-L1205.
|
| 5 |
Li G, Zhang H, Zhao L, et al. Angiotensin-converting enzyme 2 activation ameliorates pulmonary endothelial dysfunction in rats with pulmonary arterial hypertension through mediating phosphorylation of endothelial nitric oxide synthase[J]. J Am Soc Hypertens, 2017, 11(12): 842-852.
|
| 6 |
Yuan YM, Luo L, Guo Z, et al. Activation of renin-angiotensin-aldosterone system (RAAS) in the lung of smoking-induced pulmonary arterial hypertension (PAH) rats[J]. J Renin Angiotensin Aldosterone Syst, 2015, 16(2): 249-253.
|
| 7 |
Satoh M, Aso K, Nakayama T, et al. Effect of treatment with epoprostenol and endothelin receptor antagonists on the development of thyrotoxicosis in patients with pulmonary arterial hypertension[J]. Endocr J, 2017, 64(12): 1173-1180.
|
| 8 |
Jiang X, Yuan L, Li P, et al. Effect of Simvastatin on 5-HT and 5-HTT in a Rat Model of Pulmonary Artery Hypertension[J]. Cell Physiol Biochem, 2015, 37(5): 1712-1724.
|
| 9 |
Adnot S, Houssaini A, Abid S, et al. Serotonin transporter and serotonin receptors[J]. Handb Exp Pharmacol, 2013, 218: 365-380.
|
| 10 |
Oh CM, Park S, Kim H. Serotonin as a New Therapeutic Target for Diabetes Mellitus and Obesity[J]. Diabetes Metab J, 2016, 40(2): 89-98.
|
| 11 |
Rothman RB, Cadet JL, Dersch CM, et al. Altered gene expression in pulmonary tissue of tryptophan hydroxylase-1 knockout mice: implications for pulmonary arterial hypertension[J]. PLoS One, 2011, 6(3): e17735.
|
| 12 |
Kylhammar D, Radegran G. The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension[J]. Acta Physiol (Oxf), 2017, 219(4): 728-756.
|
| 13 |
Cao H, Gu H, Qiu W, et al. Association study of serotonin transporter gene polymorphisms and ventricular septal defects related possible pulmonary arterial hypertension in Chinese population[J]. Clin Exp Hypertens, 2009, 31(7): 605-614.
|
| 14 |
Wang QJ, Wang D, Tang CC. The 5-hydroxytryptamine transporter is functional in human coronary artery smooth muscle cells proliferation and is regulated by Interleukin-1 beta[J]. Int J Clin Exp Med, 2015, 8(5): 6947-6956.
|
| 15 |
Kekewska A, Gornemann T, Jantschak F, et al. Antiserotonergic properties of terguride in blood vessels, platelets, and valvular interstitial cells[J]. J Pharmacol Exp Ther, 2012, 340(2): 369-376.
|
| 16 |
Aiello RJ, Bourassa PA, Zhang Q, et al. Tryptophan hydroxylase 1 Inhibition Impacts Pulmonary Vascular Remodeling in Two Rat Models of Pulmonary Hypertension[J]. J Pharmacol Exp Ther, 2017, 360(2): 267-279.
|
| 17 |
Gray EA, Tsuchimochi H, Pearson JT, et al. Assessment of the serotonin pathway as a therapeutic target for pulmonary hypertension[J]. J Synchrotron Radiat, 2013, 20(Pt 5): 756-764.
|
| 18 |
Li BB, Jiang Z, Sheng JY, et al. Sildenafil potentiates the proliferative effect of porcine pulmonary artery smooth muscle cells induced by serotonin in vitro[J]. Chin Med J (Engl), 2011, 124(17): 2733-2740.
|
| 19 |
Olschewski H. [Appetite depressant drugs and the risk of primary pulmonary hypertension][J]. Pneumologie, 1997, 51(6): 575-576.
|
| 20 |
Kloza M, Baranowska-Kuczko M, Pedzinska-Betiuk A, et al. [Serotonin hypothesis and pulmonary artery hypertension][J]. Postepy Hig Med Dosw (Online), 2014, 68: 738-748.
|
| 21 |
Bazan IS, Fares WH. Review of the Ongoing Story of Appetite Suppressants，Serotonin Pathway, and Pulmonary Vascular Disease[J]. Am J Cardiol, 2016, 117(10): 1691-1696.
|
| 22 |
Maclean M. The serotonin hypothesis in pulmonary hypertension revisited：targets for novel therapies (2017 Grover Conference Series)[J]. Pulm Circ, 2018, 8(2): 767788587.
|
| 23 |
Gupte RS, Rawat DK, Chettimada S, et al. Activation of glucose-6-phosphate dehydrogenase promotes acute hypoxic pulmonary artery contraction[J]. J Biol Chem, 2010, 285(25): 19561-19571.
|
| 24 |
Ciuclan L, Hussey MJ, Burton V, et al. Imatinib attenuates hypoxia-induced pulmonary arterial hypertension pathology via reduction in 5-hydroxytryptamine through inhibition of tryptophan hydroxylase 1 expression[J]. Am J Respir Crit Care Med, 2013, 187(1): 78-89.
|
| 25 |
Li XQ, Wang HM, Yang CG, et al. Fluoxetine inhibited extracellular matrix of pulmonary artery and inflammation of lungs in monocrotaline-treated rats[J]. Acta Pharmacol Sin, 2011, 32(2): 217-222.
|
| 26 |
Wang HM, Wang Y, Liu M, et al. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats[J]. Can J Physiol Pharmacol, 2012, 90(11): 1506-1515.
|
| 27 |
Bhat L, Hawkinson J, Cantillon M, et al. RP5063, a novel, multimodal，serotonin receptor modulator, prevents monocrotaline-induced pulmonary arterial hypertension in rats[J]. Eur J Pharmacol, 2017, 810: 92-99.
|
| 28 |
Liu Y, Tian H, Yan X, et al. Serotonin inhibits apoptosis of pulmonary artery smooth muscle cells through 5-HT2A receptors involved in the pulmonary artery remodeling of pulmonary artery hypertension[J]. Exp Lung Res, 2013, 39(2): 70-79.
|
| 29 |
West JD, Carrier EJ, Bloodworth NC, et al. Serotonin 2B Receptor Antagonism Prevents Heritable Pulmonary Arterial Hypertension[J]. PLoS One, 2016, 11(2): e148657.
|
| 30 |
Dumitrascu R, Kulcke C, Konigshoff M, et al. Terguride ameliorates monocrotaline-induced pulmonary hypertension in rats[J]. Eur Respir J, 2011, 37(5): 1104-1118.
|
| 31 |
Morecroft I, Pang L, Baranowska M, et al. In vivo effects of a combined 5-HT1B receptor/SERT antagonist in experimental pulmonary hypertension[J]. Cardiovasc Res, 2010, 85(3): 593-603.
|
| 32 |
Hood KY, Mair KM, Harvey AP, et al. Serotonin Signaling Through the 5-HT1B Receptor and NADPH Oxidase 1 in Pulmonary Arterial Hypertension[J]. Arterioscler Thromb Vasc Biol, 2017, 37(7): 1361-1370.
|
| 33 |
Han X, Chen C, Cheng G, et al. Peroxisome proliferator-activated receptor gamma attenuates serotonin-induced pulmonary artery smooth muscle cell proliferation and apoptosis inhibition involving ERK1/2 pathway[J]. Microvasc Res, 2015, 100: 17-24.
|
| 34 |
Lopez NC, Ebensperger G, Herrera EA, et al. Role of the RhoA/ROCK pathway in high-altitude associated neonatal pulmonary hypertension in lambs[J]. Am J Physiol Regul Integr Comp Physiol, 2016, 310(11): R1053-R1063.
|
| 35 |
Bear MD, Li M, Liu Y, et al. The Lbc Rho guanine nucleotide exchange factor alpha-catulin axis functions in serotonin-induced vascular smooth muscle cell mitogenesis and RhoA/ROCK activation[J]. J Biol Chem, 2010, 285(43): 32919-32926.
|
| 36 |
Kumper S, Mardakheh FK, Mccarthy A, et al. Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis[J]. Elife, 2016, 5: e12994.
|
| 37 |
Li C, Liu PP, Tang DD, et al. Targeting the RhoA-ROCK pathway to regulate T-cell homeostasis in hypoxia-induced pulmonary arterial hypertension[J]. Pulm Pharmacol Ther, 2018, 50: 111-122.
|
| 38 |
Watts SW, Yang P, Banes AK, et al. Activation of Erk mitogen-activated protein kinase proteins by vascular serotonin receptors[J]. J Cardiovasc Pharmacol, 2001, 38(4): 539-551.
|
| 39 |
Liu Y, Suzuki YJ, Day RM, et al. Rho kinase-induced nuclear translocation of ERK1/ERK2 in smooth muscle cell mitogenesis caused by serotonin[J]. Circ Res, 2004, 95(6): 579-586.
|
| 40 |
Chung HH, Dai ZK, Wu BN, et al. KMUP-1 inhibits pulmonary artery proliferation by targeting serotonin receptors/transporter and NO synthase, inactivating RhoA and suppressing AKT/ERK phosphorylation[J]. Vascul Pharmacol, 2010, 53(5-6): 239-249.
|
| 41 |
Zhang H, Xu M, Xia J, et al. Association between serotonin transporter (SERT) gene polymorphism and idiopathic pulmonary arterial hypertension: a meta-analysis and review of the literature[J]. Metabolism, 2013, 62(12): 1867-1875.
|
| 42 |
Johansen AK, Dean A, Morecroft I, et al. The serotonin transporter promotes a pathological estrogen metabolic pathway in pulmonary hypertension via cytochrome P450 1B1[J]. Pulm Circ, 2016, 6(1): 82-92.
|
| 43 |
Ali Z, Waseem M, Kumar R, et al. Unveiling the interactions among BMPR-2, ALK-1 and 5-HTT genes in the pathophysiology of HAPE[J]. Gene, 2016, 588(2): 163-172.
|
| 44 |
Kao WT, Chang CL, Lung FW. 5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial[J]. J Affect Disord, 2018, 238: 597-608.
|
| 45 |
Phi VD, Muhlbauer E, Phi-Van L. Histone deacetylase HDAC1 downregulates transcription of the serotonin transporter (5-HTT) gene in tumor cells[J]. Biochim Biophys Acta, 2015, 1849(8): 909-918.
|
| 46 |
Jiao YR, Wang W, Lei PC, et al. 5-HTT, BMPR2, EDN1, ENG, KCNA5 gene polymorphisms and susceptibility to pulmonary arterial hypertension: A meta-analysis[J]. Gene, 2019, 680: 34-42.
|
| 47 |
Saito YA, Larson JJ, Atkinson EJ, et al. The role of 5-HTT LPR and GNbeta3 825C>；T polymorphisms and gene-environment interactions in irritable bowel syndrome (IBS)[J]. Dig Dis Sci, 2012, 57(10): 2650-2657.
|
| 48 |
Baloira A, Nunez M, Cifrian J, et al. Polymorphisms in the serotonin transporter protein (SERT) gene in patients with pulmonary arterial hypertension[J]. Arch Bronconeumol, 2012, 48(3): 77-80.
|
| 49 |
Ulasli SS, Eyuboglu FO, Verdi H, et al. Associations between endothelial nitric oxide synthase A/B, angiotensin converting enzyme I/D and serotonin transporter L/S gene polymorphisms with pulmonary hypertension in COPD patients[J]. Mol Biol Rep, 2013, 40(10): 5625-5633.
|
| 50 |
Cao H, Gu H, Qiu W, et al. Association study of serotonin transporter gene polymorphisms and ventricular septal defects related possible pulmonary arterial hypertension in Chinese population[J]. Clin Exp Hypertens, 2009, 31(7): 605-614.
|
| 51 |
Bazan IS, Fares WH. Review of the Ongoing Story of Appetite Suppressants，Serotonin Pathway, and Pulmonary Vascular Disease[J]. Am J Cardiol, 2016, 117(10): 1691-1696.
|